1Adsay NV, Fukushima N, Furukawa T, Hruban RH, Klimstra DH,Kl-ppel G, Offerhaus GJA, Pitman MB, Shimizu M, Zamboni G.Intraductal neoplasms of the pancreas. In: Bosman FT, CarneiroF, Hruban RH, Theise ND. WHO classification of tumors of thedigestive system. Lyon: IARC Press, 2010: 304-313.
2Kobari M, Egawa S, Shibuya K, Shimamura H, SunamuraM, Takeda K, Matsuno S, Furukawa T. Intraductal papillarymucinous tumors of the pancreas comprise 2 clinical subtypes:differences in clinical characteristics and surgical management.Arch Surg 1999; 134: 1131-1136 [PMID: 10522860 DOI: 10.1001/archsurg.134.10.1131].
3Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G,Bernades P, Belghiti J, Ruszniewski P, Fléjou JF. Intraductalpapillary mucinous tumors of the pancreas confined to secondaryducts show less aggressive pathologic features as compared withthose involving the main pancreatic duct. Am J Surg Pathol 2000;24: 1372-1377 [PMID: 11023098 DOI: 10.1097/00000478-200010000-00006].
4Matsumoto T, Aramaki M, Yada K, Hirano S, Himeno Y, ShibataK, Kawano K, Kitano S. Optimal management of the branch ducttype intraductal papillary mucinous neoplasms of the pancreas.J Clin Gastroenterol 2003; 36: 261-265 [PMID: 12590239 DOI:10.1097/00004836-200303000-00014].
5Lévy P, Jouannaud V, O'Toole D, Couvelard A, Vullierme MP,Palazzo L, Aubert A, Ponsot P, Sauvanet A, Maire F, Hentic O,Hammel P, Ruszniewski P. Natural history of intraductal papillarymucinous tumors of the pancreas: actuarial risk of malignancy.Clin Gastroenterol Hepatol 2006; 4: 460-468 [PMID: 16616351DOI: 10.1016/j.cgh.2006.01.018].
6Kang MJ, Jang JY, Kim SJ, Lee KB, Ryu JK, Kim YT, YoonYB, Kim SW. Cyst growth rate predicts malignancy in patientswith branch duct intraductal papillary mucinous neoplasms. ClinGastroenterol Hepatol 2011; 9: 87-93 [PMID: 20851216 DOI:10.1016/j.cgh.2010.09.008].
7Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, FalconiM, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. Internationalconsensus guidelines for management of intraductal papillarymucinous neoplasms and mucinous cystic neoplasms of thepancreas. Pancreatology 2006; 6: 17-32 [PMID: 16327281 DOI:10.1159/000090023].
8Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M,Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, ShimizuM, Wolfgang CL, Yamaguchi K, Yamao K. International consensusguidelines 2012 for the management of IPMN and MCN of thepancreas. Pancreatology 2012; 12: 183-197 [PMID: 22687371DOI: 10.1016/j.pan.2012.04.004].
9Kubo H, Chijiiwa Y, Akahoshi K, Hamada S, Harada N, Sumii T,Takashima M, Nawata H. Intraductal papillary-mucinous tumors ofthe pancreas: differential diagnosis between benign and malignanttumors by endoscopic ultrasonography. Am J Gastroenterol 2001;96: 1429-1434 [PMID: 11374678].
10Kobayashi G, Fujita N, Noda Y, Ito K, Horaguchi J, TakasawaO, Akaishi S, Tsuchiya T, Kobari M. Mode of progression ofintraductal papillary-mucinous tumor of the pancreas: analysisof patients with follow-up by EUS. J Gastroenterol 2005; 40:744-751 [PMID: 16082592 DOI: 10.1007/s00535-005-1619-7].
